<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-151005" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Benign and Malignant Iris Tumors</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Moshirfar</surname>
            <given-names>Majid</given-names>
          </name>
          <aff>University of Utah/John Moran Eye Center; Hoopes Vision/HDR Research Center; Utah Lions Eye Bank</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rageh</surname>
            <given-names>Abdulrahman</given-names>
          </name>
          <aff>Prairie Eye Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ronquillo</surname>
            <given-names>Yasmyne</given-names>
          </name>
          <aff>Hoopes Vision Research Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Majid Moshirfar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdulrahman Rageh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yasmyne Ronquillo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-151005.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Iris tumors are relatively infrequent compared to similar ciliary tumors but comprise a broad spectrum of benign and malignant pathologies. Due to the lack of metastatic potential, benign iris tumors generally offer a more favorable prognosis than malignant lesions. However, even benign iris tumors can threaten vision.</p>
        <p>Benign iris tumors can be broadly categorized as either cystic or solid. Cystic lesions tend to be stable over time and exhibit well-defined, predictable behavior. Solid iris tumors encompass a wide range of melanocytic and nonmelanocytic variants.<xref ref-type="bibr" rid="article-151005.r1">[1]</xref>&#x000a0;The most commonly encountered malignant iris tumor is melanoma, which has significant metastatic potential.</p>
        <p>This activity reviews the epidemiology, etiology, clinical manifestations, evaluation methods, histopathology, treatment modalities, and prognosis of iris tumors. Categorizing these tumors by origin, such as melanomas, adenocarcinomas, metastases, and benign neoplasms, permits a tailored approach to each tumor subtype.</p>
        <p>The iris tumor variants discussed in this article include:</p>
        <p>
<bold>Malignant Lesions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Metastases to the iris</p>
          </list-item>
          <list-item>
            <p>Iris melanoma</p>
          </list-item>
          <list-item>
            <p>Iris pigment epithelium adenocarcinoma</p>
          </list-item>
        </list>
        <p>
<bold>Benign Lesions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Iris cysts</p>
          </list-item>
          <list-item>
            <p>Iris nevus</p>
          </list-item>
          <list-item>
            <p>Iris pigment epithelium adenoma</p>
          </list-item>
          <list-item>
            <p>Iris leiomyoma</p>
          </list-item>
          <list-item>
            <p>Iridic nodules</p>
          </list-item>
          <list-item>
            <p>Vascular tumors of the iris.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-151005.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>
<bold>Malignant Lesions</bold>
</p>
        <p>
<bold>Metastases to the iris </bold>
</p>
        <p>Metastatic iridic lesions primarily originate from breast or lung carcinomas, accounting for 37% and 27% of iris metastases, respectively. Other frequent primary sites include the kidney (8%), the gastrointestinal tract (8%), and the prostate (2%).<xref ref-type="bibr" rid="article-151005.r1">[1]</xref><xref ref-type="bibr" rid="article-151005.r2">[2]</xref></p>
        <p>
<bold>Iris melanoma</bold>
</p>
        <p>Most iris melanomas are composed of spindle cells. <italic toggle="yes">BAP1</italic> is a major tumor suppressor, and germline&#x000a0;<italic toggle="yes">BAP1</italic> mutations predispose to uveal melanoma and other malignancies.<xref ref-type="bibr" rid="article-151005.r3">[3]</xref>&#x000a0;More than 75% of iris melanomas originate in the inferior half of the iris.<xref ref-type="bibr" rid="article-151005.r4">[4]</xref>&#x000a0;While the role of UV exposure in developing iris melanoma remains unclear, data strongly suggests a synergistic risk between light-colored irises, UV exposure, and uveal melanoma.<xref ref-type="bibr" rid="article-151005.r4">[4]</xref>&#x000a0;Uveal melanomas have a 30% greater incidence in male patients, although the incidence varies with geographic location. In the United States, the incidence is highest in non-Hispanic White people, with an estimated rate of 6.02 per million. The incidence of iris melanoma also increased with increasing latitude in Europe.<xref ref-type="bibr" rid="article-151005.r5">[5]</xref></p>
        <p>
<bold>Iris pigment epithelium adenoma and adenocarcinoma</bold>
</p>
        <p>Iris adenomatous proliferations are of neuroectodermal origin, differentiating them from melanomatous proliferations with neural crest origins.<xref ref-type="bibr" rid="article-151005.r6">[6]</xref></p>
        <p>
<bold>Benign Lesions</bold>
</p>
        <p>
<bold>Iris cysts</bold>
</p>
        <p>Iris cysts may be primary or secondary. Primary iris cysts are composed of iris stroma or pigment epithelium. Secondary iris cysts result from external factors including but not limited to trauma, parasitic infection, or iatrogenic injury. Distinguishing cysts from other lesions of the iris is challenging because of the vast number of etiologic possibilities.<xref ref-type="bibr" rid="article-151005.r1">[1]</xref></p>
        <p>
<bold>Iris nevus</bold>
</p>
        <p>Iridic nevi are of melanocytic origin and are often considered precursor lesions to malignant melanoma. A retrospective study of 1611 patients with an iris nevus revealed a 15-year conversion rate to melanoma of 8%.<xref ref-type="bibr" rid="article-151005.r7">[7]</xref></p>
        <p>
<bold>Iris leiomyoma</bold>
</p>
        <p>Iris leiomyomas are incredibly rare ocular lesions. Improved diagnostic capabilities have decreased the number of iris leiomyoma diagnoses; many lesions previously thought to be a leiomyoma are now classified as spindle cell nevi or low-grade melanomas.<xref ref-type="bibr" rid="article-151005.r8">[8]</xref></p>
        <p>
<bold>Iridic nodules</bold>
</p>
        <p>Brushfield and Wolffilin spots are iris nodules that have been historically used as markers of trisomy 21; they are now considered clinically insignificant, and their exclusive association with light irises remains unexplained. Lisch nodules, characteristic of neurofibromatosis type 1 (NF1), are dome-shaped melanocytic hamartomas on the iris surface that may appear clear, yellow, or brown. Lisch nodules are almost always present in patients with NF1 after 6 years of age and are one of the most common ocular pathognomonic markers for NF1.<xref ref-type="bibr" rid="article-151005.r9">[9]</xref></p>
        <p>The presence of inflammatory iris nodules suggests systemic conditions like Vogt-Koyanagi-Harada syndrome, sarcoidosis, multiple sclerosis, or Fuchs heterochromic iridocyclitis. Infection with treponemes, mycobacteria, or&#x000a0;rickettsiae has been linked to the formation of iris nodules.<xref ref-type="bibr" rid="article-151005.r10">[10]</xref>&#x000a0;Nodules may also be drug-induced or due to juvenile xanthogranuloma.</p>
        <p>
<bold>Vascular tumors of the iris</bold>
</p>
        <p>Iridic vascular tumors are most frequently a manifestation of systemic pathology, such as hereditary hemorrhagic telangiectasia. Vascular tumors of the iris may infrequently be isolated arteriovenous malformations.<xref ref-type="bibr" rid="article-151005.r11">[11]</xref></p>
      </sec>
      <sec id="article-151005.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>
<bold>Malignant Lesions</bold>
</p>
        <p>
<bold>Metastases to the Iris</bold>
</p>
        <p>Despite being considered the most common intraocular malignancy, metastases to the iris only constitute&#x000a0;approximately 2% of all iris tumors and 8% of all metastases to the eye.<xref ref-type="bibr" rid="article-151005.r2">[2]</xref></p>
        <p>
<bold>Iris melanoma</bold>
</p>
        <p>Iris melanomas account for 3% to 10% of uveal melanomas; the iris is the least common primary site for malignant melanoma.<xref ref-type="bibr" rid="article-151005.r1">[1]</xref> However, melanoma is the most prevalent type of iris neoplasm, representing about 68% of all iris tumors. Notably, iris melanomas exhibit no preference for eye laterality or gender in populations younger than 65 years old; there is a higher incidence in men older than 65 years.<xref ref-type="bibr" rid="article-151005.r12">[12]</xref></p>
        <p>
<bold>Iris pigment epithelium adenocarcinoma</bold>
</p>
        <p>This neoplasm of pigment epithelium is exceedingly rare; approximately 1 case is reported annually in the United States. Published case reports are few.<xref ref-type="bibr" rid="article-151005.r6">[6]</xref><xref ref-type="bibr" rid="article-151005.r13">[13]</xref></p>
        <p>
<bold>Benign Lesions</bold>
</p>
        <p>
<bold>Iris cysts</bold>
</p>
        <p>Iris cysts are considered rare in the broader context of all ocular tumors. However, cystic lesions are a relatively frequent iris lesion. Shields et al reported that 21% of 3680 documented iris tumors were cystic lesions.<xref ref-type="bibr" rid="article-151005.r1">[1]</xref></p>
        <p>
<bold>Iris nevus</bold>
</p>
        <p>Iris nevi are rarely seen in childhood. However, these flat, pigmented lesions may be single or multifocal and are seen in almost 50% of adults.<xref ref-type="bibr" rid="article-151005.r14">[14]</xref></p>
        <p>
<bold>Iris pigment epithelium adenoma</bold>
</p>
        <p>Iris pigment epithelium adenoma accounted for less than 1% of iris tumors in a study of 3680 cases.&#x000a0;Their rarity makes it challenging to establish predilections for age and gender; the suggested median age of diagnosis is 60 years.<xref ref-type="bibr" rid="article-151005.r15">[15]</xref><xref ref-type="bibr" rid="article-151005.r16">[16]</xref></p>
        <p>
<bold>Iris leiomyoma</bold>
</p>
        <p>Generally favoring females and younger individuals, intraocular leiomyomata are exceptionally rare.<xref ref-type="bibr" rid="article-151005.r17">[17]</xref></p>
        <p>
<bold>Iridic nodules</bold>
</p>
        <p>Brushfield and Wolfillin spots&#x000a0;are seen in approximately 10% of the population; the incidence increases from 21% to 63% when using infrared photography.<xref ref-type="bibr" rid="article-151005.r18">[18]</xref>&#x000a0;Lisch nodules are usually bilateral and multifocal; the occurrence of NF1 in the general population approximates 1 in 3500 live births.<xref ref-type="bibr" rid="article-151005.r9">[9]</xref>&#x000a0;Other nodule types are exceedingly uncommon&#x000a0;and lack substantial supportive epidemiological data.<xref ref-type="bibr" rid="article-151005.r10">[10]</xref></p>
        <p>
<bold>Vascular tumors of the iris</bold>
</p>
        <p>Racemose hemangiomas are the dominant vascular tumor of the iris; this was reflected in a study demonstrating an incidence of 65% in patients with iridic vascular neoplasms. Cavernous hemangiomas, varix, microhemangiomatosis, arteriovenous malformation, and pediatric capillary hemangiomas collectively accounted for the remaining 35%. These tumors primarily affect middle-aged and older adults, are often unilateral, and display no gender preference.<xref ref-type="bibr" rid="article-151005.r11">[11]</xref><xref ref-type="bibr" rid="article-151005.r19">[19]</xref></p>
      </sec>
      <sec id="article-151005.s4" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>
<bold>Malignant Lesions</bold>
</p>
        <p>
<bold>Metastases to the iris</bold>
</p>
        <p>The histopathology of metastases to the iris typically reflects the cytologic architecture of the primary neoplasm.<xref ref-type="bibr" rid="article-151005.r2">[2]</xref></p>
        <p>
<bold>Iris melanoma</bold>
</p>
        <p>Melanoma cells are&#x000a0;typically either spindle-shaped or epithelioid. Spindle cells exhibit elongated nuclei, mildly coarse chromatin, and eosinophilic nucleoli. Epithelioid cells possess abundant eosinophilic cytoplasm, have distinct cell borders, and tend to be larger and pleomorphic. Some melanomas can comprise spindle and epithelioid cells (see <bold>Image</bold>.&#x000a0;Iris Melanoma Markers).<xref ref-type="bibr" rid="article-151005.r5">[5]</xref><xref ref-type="bibr" rid="article-151005.r20">[20]</xref>&#x000a0;</p>
        <p>
<bold>Iris pigment epithelium adenoma and adenocarcinoma</bold>
</p>
        <p>Iris pigment epithelial adenomas are thought to be premalignant lesions; adenomas and adenocarcinomas share histologic characteristics. Iris pigment epithelium consists of heavily pigmented polygonal cells organized in sheets and cords. These tumors&#x000a0;may be avascular with thin-walled vessels. Adenocarcinomas may exhibit tubuloacinar configurations. Infrequent mitotic figures and pleomorphic nuclei can be observed among cells with distinct borders and abundant cytoplasm.<xref ref-type="bibr" rid="article-151005.r21">[21]</xref></p>
        <p>
<bold>Benign Lesions</bold>
</p>
        <p>
<bold>Iris cysts</bold>
</p>
        <p>Pigment epithelium cysts originating from the central or mid-zonal iris are composed of heavily pigmented columnar cells. Peripheral iris pigment epithelium cysts are partially lined with nonpigmented cells and may appear semitranslucent. Histologically, stromal cysts display stratified squamous epithelium or single layers of cuboidal cells often interspersed with goblet cells. This appearance suggests an ectodermal origin, potentially arising from surface ectoderm cells trapped in the stroma during embryogenesis.<xref ref-type="bibr" rid="article-151005.r22">[22]</xref><xref ref-type="bibr" rid="article-151005.r23">[23]</xref></p>
        <p>
<bold>Iris nevus</bold>
</p>
        <p>Iris nevi cells are atypical and melanocytic yet benign by histological criteria. Predominantly spindle cells, these fusiform melanocytes typically possess small nuclei with either a small or absent nucleolus.<xref ref-type="bibr" rid="article-151005.r5">[5]</xref></p>
        <p>
<bold>Iris leiomyoma</bold>
</p>
        <p>Histologically, iris leiomyomas are characterized by spindle-shaped smooth muscle cells arranged in fascicles. These cells feature elongated, cigar-shaped nuclei and eosinophilic cytoplasm and are supported by a collagenous stroma. Immunohistochemical markers such&#x000a0;as smooth muscle actin and desmin may offer diagnostic confirmation of leiomyomatous origin.<xref ref-type="bibr" rid="article-151005.r8">[8]</xref></p>
        <p>
<bold>Vascular tumors of the iris</bold>
</p>
        <p>These tumors often exhibit the cavernous vasculature&#x000a0;commonly seen in&#x000a0;vascular tumors. However, caution is advised; a study by Ferry revealed significant misdiagnosis of vascular tumors over melanomas and juvenile xanthogranulomas, as large vessels can obscure spindle cells and granular inflammation.<xref ref-type="bibr" rid="article-151005.r24">[24]</xref></p>
      </sec>
      <sec id="article-151005.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with iris tumors often&#x000a0;have a&#x000a0;discoloration or spot on the iris&#x000a0;that is noticeable to them. Distorted or blurred vision is possible but uncommon, as is pain. A comprehensive medical history should be obtained, including inquiries into recent travel, trauma, and exposure to ocular foreign bodies.<xref ref-type="bibr" rid="article-151005.r1">[1]</xref></p>
        <p>
<bold>Malignant Lesions</bold>
</p>
        <p>
<bold>Metastases to the iris</bold>
</p>
        <p>Metastatic lesions of the iris are typically discovered after locating the primary neoplasm and usually appear amelanotic. Metastases can induce cellular shedding, resulting in hypopyon, clogging of the trabecular meshwork with subsequent increased intraocular pressure,&#x000a0;or spontaneous hyphema.<xref ref-type="bibr" rid="article-151005.r2">[2]</xref></p>
        <p>
<bold>Iris melanoma</bold>
</p>
        <p>The most common sign of iris melanoma is a visible, elevated, dark, or amelanotic spot. Iris melanomas exhibit either a circumscribed (90%) or diffuse (10%) growth pattern.<xref ref-type="bibr" rid="article-151005.r25">[25]</xref>&#x000a0;Circumscribed melanomas usually have a flat or rounded anterior contour and are yellow or brown. Diffuse melanomas lack focal thickening and heterochromia, frequently involve the trabecular meshwork, and increase intraocular pressure.<xref ref-type="bibr" rid="article-151005.r12">[12]</xref>&#x000a0;Irregularly contoured lesions thicker than 0.5 to 1.0 mm are concerning for malignancy; increased vasculature, spontaneous hyphema formation, and pupillary peeking are also concerning features.<xref ref-type="bibr" rid="article-151005.r5">[5]</xref>&#x000a0;The mnemonic ABCDEF for Age, Blood, Clock hour, Diffuse configuration, Ectropion, and Feathery margins can aid assessment.<xref ref-type="bibr" rid="article-151005.r1">[1]</xref><xref ref-type="bibr" rid="article-151005.r7">[7]</xref></p>
        <p>
<bold>Iris pigment epithelium adenocarcinoma</bold>
</p>
        <p>These tumors present as darkly pigmented, possibly multinodular masses. Patients are usually asymptomatic; vision loss is a possible symptom.<xref ref-type="bibr" rid="article-151005.r6">[6]</xref></p>
        <p>
<bold>Benign Lesions</bold>
</p>
        <p>
<bold>Iris cysts</bold>
</p>
        <p>Pigment epithelium cysts are unilateral, darker structures that transilluminate.&#x000a0;Stromal cysts are typically seen in the first decade of life and have a smooth, translucent anterior wall. Both cyst types can dislodge and become free-floating masses in the anterior chamber or vitreous; this is rare.<xref ref-type="bibr" rid="article-151005.r1">[1]</xref></p>
        <p>
<bold>Iris nevus</bold>
</p>
        <p>Nevi are typically smaller than melanomas,&#x000a0;measuring&#x000a0;less than 3mm in diameter and 1mm thick. Nevi occurring in conjunction with iridocorneal endothelial syndrome present as flat, pigmented lesions, often accompanied by stromal flattening, ectropion uvea, and pupil abnormalities.<xref ref-type="bibr" rid="article-151005.r7">[7]</xref></p>
        <p>
<bold>Iris pigment epithelium adenoma</bold>
</p>
        <p>These neoplasms typically appear as a dark grey lesion at the iridic periphery, although they may be multinodular. Iris pigment epithelium adenomas can cause anterior displacement, stromal thinning, and erosion.<xref ref-type="bibr" rid="article-151005.r6">[6]</xref><xref ref-type="bibr" rid="article-151005.r15">[15]</xref></p>
        <p>
<bold>Iris leiomyoma</bold>
</p>
        <p>Leiomyomata of the iris are typically solitary, slow-growing, well-demarcated, nodular lesions that may be nonpigmented or lightly pigmented.<xref ref-type="bibr" rid="article-151005.r8">[8]</xref></p>
        <p>
<bold>Iridic nodules</bold>
</p>
        <p>Inflammatory nodules are accompanied by cells in the anterior chamber or vitreous; aqueous flare and fibrin clot formation are frequent. Inflammatory nodules are lighter in color than Brushfield spots and Lisch nodules.<xref ref-type="bibr" rid="article-151005.r10">[10]</xref>&#x000a0;As iridic nodules are often a manifestation of systemic disease, a physical examination should be performed to assess the presence of skin lesions or splinter hemorrhages.<xref ref-type="bibr" rid="article-151005.r10">[10]</xref><xref ref-type="bibr" rid="article-151005.r26">[26]</xref>&#x000a0;Yellow iridic nodules with hyphema and concomitant skin lesions suggest juvenile xanthogranulomas.<xref ref-type="bibr" rid="article-151005.r27">[27]</xref>&#x000a0;If sarcoidosis is suspected, chest imaging is recommended.</p>
        <p>
<bold>Vascular tumors of the iris</bold>
</p>
        <p>Vascular iridic tumors frequently present with spontaneous hyphema and subsequent blurred vision. Visualization of similar vascular anomalies elsewhere on the body&#x000a0;may suggest an underlying systemic disorder; a thorough skin examination is recommended.<xref ref-type="bibr" rid="article-151005.r24">[24]</xref></p>
      </sec>
      <sec id="article-151005.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Patients with iris tumors require a thorough examination with the slit lamp biomicroscope. Measurement of intraocular pressure (IOP) is recommended due to the glaucomatous potential of many iris tumors, and gonioscopy should be performed. Transillumination is a valuable tool when&#x000a0;determining the nature of the&#x000a0;lesion.<xref ref-type="bibr" rid="article-151005.r8">[8]</xref>&#x000a0;B-scan and ultrasound biomicroscopy (UBM) are also excellent diagnostic tools.<xref ref-type="bibr" rid="article-151005.r28">[28]</xref><xref ref-type="bibr" rid="article-151005.r29">[29]</xref></p>
        <p>
<bold>Malignant Lesions</bold>
</p>
        <p>
<bold>Metastases to the iris</bold>
</p>
        <p>If the primary site of malignancy is unknown, a limbal puncture can be performed to obtain cells for histologic examination. A B-scan of the lesion will typically reveal an echodense mass.<xref ref-type="bibr" rid="article-151005.r2">[2]</xref></p>
        <p>
<bold>Iris melanoma</bold>
</p>
        <p>Transpupillary, transconjunctival, or transscleral illumination can be employed to assess if the shadow of the lesion extends to the pars plicata or pars plana regions and determine the posterior extent of the lesion.<xref ref-type="bibr" rid="article-151005.r25">[25]</xref>&#x000a0;Serial slit lamp photography can be used to follow lesional growth and contour changes. While smaller melanomas are typically well-visualized with anterior segment optical coherence tomography (AS-OCT), complete visualization of larger tumors frequently requires additional imaging techniques such as B-scan or UBM&#x000a0; (see <bold>Image.</bold> Iris Melanoma Mass on Tomography). B-scan is typically the superior imaging technique for large lesions; sound waves better penetrate the ocular structures than the light waves of AS-OCT.<xref ref-type="bibr" rid="article-151005.r12">[12]</xref>&#x000a0;Fluorescein angiogram or optical coherence tomography angiography (OCTA) is particularly helpful when evaluating vascular melanomas, which often exhibit a late filling pattern. Incisional for fine-needle biopsy&#x000a0;can be considered for suspicious lesions that cannot be confidently diagnosed by clinical features alone.<xref ref-type="bibr" rid="article-151005.r5">[5]</xref><xref ref-type="bibr" rid="article-151005.r30">[30]</xref></p>
        <p>
<bold>Iris pigment epithelium adenoma and adenocarcinoma</bold>
</p>
        <p>Examination with the slit lamp biomicroscope may&#x000a0;reveal significant tissue erosion. However, as the literature about these tumors is sparse, ultrasound and biopsy should be performed.<xref ref-type="bibr" rid="article-151005.r6">[6]</xref></p>
        <p>
<bold>Benign Lesions</bold>
</p>
        <p>
<bold>Iris cysts</bold>
</p>
        <p>B-scan and UBM aid in determining the extent of the lesion and distinguishing solid from cystic lesions. The shadowing of otherwise high-resolution images may limit the utility of AS-OCT. Fine needle aspiration may be necessary when noninvasive methods fail to confirm diagnosis.<xref ref-type="bibr" rid="article-151005.r22">[22]</xref><xref ref-type="bibr" rid="article-151005.r28">[28]</xref><xref ref-type="bibr" rid="article-151005.r29">[29]</xref></p>
        <p>
<bold>Iris nevus</bold>
</p>
        <p>Fluorescein angiogram or OCTA can be employed to evaluate iridic nevi; many studies indicate these studies offer little prognostic value. Most nevi exhibit a filling pattern of early hyperfluorescence and late leaking; melanomas have irregular vasculature and fill late. The utility of OCTA is somewhat limited; light waves penetrate highly pigmented lesions poorly.<xref ref-type="bibr" rid="article-151005.r7">[7]</xref><xref ref-type="bibr" rid="article-151005.r31">[31]</xref>&#x000a0;B-Scan can be used to determine the size of the neoplasm, and FNA can be performed to determine the histopathology definitively.<xref ref-type="bibr" rid="article-151005.r5">[5]</xref></p>
        <p>
<bold>Iris leiomyoma</bold>
</p>
        <p>Immunohistochemistry and electron microscopy are essential confirmatory diagnostic tests for iridic leiomyomata, as these lesions are histopathologically complex and frequently mimic other neoplasms. Any potential angle involvement must be evaluated as secondary glaucoma is a common sequela.<xref ref-type="bibr" rid="article-151005.r8">[8]</xref><xref ref-type="bibr" rid="article-151005.r32">[32]</xref></p>
        <p>
<bold>Iridic nodules</bold>
</p>
        <p>Anterior chamber paracentesis can be performed if the etiology of the nodule remains unclear after a comprehensive history is taken and a physical examination is performed. Paracentesis fluid can be sent for cytology, histologic evaluation, and culture.&#x000a0;</p>
        <p>
<bold>Vascular tumors of the iris</bold>
</p>
        <p>Angiography, particularly fluorescein angiogram, is crucial when evaluating vascular tumors of the iris. Biopsy is rarely necessary but can be performed if angiography is nonconfirmatory.<xref ref-type="bibr" rid="article-151005.r24">[24]</xref></p>
      </sec>
      <sec id="article-151005.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Malignant Lesions</bold>
</p>
        <p>
<bold>Metastases to the iris</bold>
</p>
        <p>Metastatic disease to the iris is non&#x02013;life-threatening and rarely the initial presentation of a malignancy. Patients with metastatic disease to the iris are frequently already on systemic hormonal or chemotherapeutic regimens. The goal in treating iridic metastases is to preserve vision whenever possible. Consultation with the medical or surgical oncologist is warranted to assess the utility of systemic regimen modifications. Additionally, consultation with the ophthalmic oncologist for local radiation therapy with either EBRT or plaque radiotherapy may be indicated.<xref ref-type="bibr" rid="article-151005.r2">[2]</xref></p>
        <p>
<bold>Iris melanoma</bold>
</p>
        <p>The treatment of iris melanoma is dictated by the clinical characteristics and behavior of the lesion. Small, well-circumscribed lesions may be closely followed with serial imaging and regular evaluation of intraocular pressure (see <bold>Image.</bold> Malignant Melanoma of Iris Typical Presentation.)<xref ref-type="bibr" rid="article-151005.r30">[30]</xref>&#x000a0;Proton beam therapy or plaque radiotherapy is indicated for extensive tumor seeding or nonresectable tumors; these treatments can result in vision loss. Surgical partial iridectomy may be a treatment option for symptomatic smaller melanomas. Iridotrabeculectomy may be indicated if the melanoma has invaded the trabecular meshwork. Iridocyclectomy is typically reserved for tumors exhibiting mild-to-moderate ciliary body invasion (see <bold>Image</bold>.&#x000a0;Melanotic Malignant Melanoma.) Neoplasms that are large, diffuse, recurrent, or significantly impacting vision may require enucleation.<xref ref-type="bibr" rid="article-151005.r12">[12]</xref></p>
        <p>
<bold>Iris pigment epithelium adenocarcinoma</bold>
</p>
        <p>Treatment options include chemotherapy, radiation, surgical excision, or enucleation, depending on the size and invasiveness of the tumor.<xref ref-type="bibr" rid="article-151005.r6">[6]</xref></p>
        <p>
<bold>Benign Lesions</bold>
</p>
        <p>
<bold>Iris cysts</bold>
</p>
        <p>Close observation is recommended if the cyst is stable, vision is not impacted, and the patient is asymptomatic. Intervention is warranted if the cyst increases in size or the patient becomes symptomatic. Noninvasive therapy is initially recommended via laser therapy or cyst aspiration with or without injection of sclerosing agents. Surgical excision can be considered if conservative efforts fail.<xref ref-type="bibr" rid="article-151005.r22">[22]</xref></p>
        <p>
<bold>Iris nevus</bold>
</p>
        <p>Iris nevi are histologically benign, and observation is recommended. Small, unsuspicious nevi may be imaged every 12 to 24 months. Large, unsuspicious nevi may be imaged every 6 to 12 months. Nevi with suspicious characteristics should be closely followed, with comprehensive ophthalmologic evaluation and imaging every 1 to 3 months. Once the stability of a nevus has been documented, patients can be evaluated annually (see <bold>Image.&#x000a0;</bold>Iris Nevus).<xref ref-type="bibr" rid="article-151005.r5">[5]</xref></p>
        <p>
<bold>Iris pigment epithelium adenoma</bold>
</p>
        <p>The management of an iris pigment epithelium adenoma is dictated by the presence of symptoms and the size and location of the tumor. Small, asymptomatic lesions may be managed conservatively with regular clinical evaluation. Adenomas that are large or symptomatic may be excised via iridocyclectomy or en bloc resection.<xref ref-type="bibr" rid="article-151005.r16">[16]</xref></p>
        <p>
<bold>Iris leiomyoma</bold>
</p>
        <p>Iris leiomyomata are typically slow-growing, and observation with periodic monitoring may be a suitable approach for small, asymptomatic lesions. In a study by Tomar et al of 14 patients with bothersome leiomyomata, 1 patient underwent radiation therapy, and 13 underwent surgical excision via either iridectomy or iridocyclectomy. However, therapeutic enucleation has been employed for actively enlarging neoplasms or those invading the angle.<xref ref-type="bibr" rid="article-151005.r8">[8]</xref><xref ref-type="bibr" rid="article-151005.r32">[32]</xref></p>
        <p>
<bold>Iridic nodules</bold>
</p>
        <p>The treatment of an iridic nodule is dictated by the underlying etiology of the lesion. Infectious nodules should be treated with organism-specific systemic antimicrobial therapy; intraocular injection can be considered when systemic treatments fail.<xref ref-type="bibr" rid="article-151005.r10">[10]</xref>&#x000a0;Sarcoid iridic nodules typically respond to the immunosuppressive regimens employed to control systemic disease; local excision may be required to preserve or improve vision outcomes.<xref ref-type="bibr" rid="article-151005.r33">[33]</xref>&#x000a0;Drug-induced nodules, most commonly caused by propanolol, typically recede with discontinuation of the offending medication.<xref ref-type="bibr" rid="article-151005.r34">[34]</xref>&#x000a0;Patients with NF1 and Lisch nodules require regular observation due to the increased risk of malignant transformation.</p>
        <p>
<bold>Vascular tumors of the iris</bold>
</p>
        <p>Most vascular tumors of the iris are asymptomatic and require only regular observation. Serial&#x000a0;imaging is recommended to&#x000a0;evaluate and document any growth or architectural changes.<xref ref-type="bibr" rid="article-151005.r11">[11]</xref></p>
      </sec>
      <sec id="article-151005.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for an iris lesion should include all&#x000a0;iris tumors. Additional pathologic processes that may mimic a neoplasm include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Inflammatory granuloma</p>
          </list-item>
          <list-item>
            <p>Epithelial ingrowth</p>
          </list-item>
          <list-item>
            <p>Congenital iris heterochromia</p>
          </list-item>
          <list-item>
            <p>Fuchs heterochromic iridocyclitis</p>
          </list-item>
          <list-item>
            <p>Iris nevus syndrome</p>
          </list-item>
          <list-item>
            <p>Pigment dispersion</p>
          </list-item>
          <list-item>
            <p>Hemosiderosis</p>
          </list-item>
          <list-item>
            <p>Pigmentary glaucoma</p>
          </list-item>
          <list-item>
            <p>Ocular siderosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-151005.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>
<bold>Malignant Lesions</bold>
</p>
        <p>
<bold>Metastases to the iris</bold>
</p>
        <p>While untreated metastatic carcinomas carry an extremely poor ocular prognosis, overall prognosis and mortality are dictated by the tissue of origin. Cancers with uveal-type metastases, including iris metastases, have a cumulative overall survival rate of 32% at 3 years and 24% at 5 years. However, carcinoid tumors that metastasize to the iris have the most favorable 5-year survival rates at 92%, while kidney and pancreatic cancers that metastasize to the iris have 5-year survival rates of 0%.<xref ref-type="bibr" rid="article-151005.r2">[2]</xref></p>
        <p>
<bold>Iris melanoma</bold>
</p>
        <p>A retrospective study by Sabazade et al observed the 5-year mortality rate for iris melanoma&#x000a0;to be&#x000a0;5%, rising to 8% at 10 to 20 years.<xref ref-type="bibr" rid="article-151005.r25">[25]</xref>&#x000a0;Histopathologic subtype and tumor size influence the prognosis of iris melanoma. Spindle cell melanomas generally have a better prognosis than epithelioid or mixed cell types; epithelioid melanoma is the more aggressive neoplasm. Local invasion of the choroid or ciliary body portends a worse prognosis. Diffuse melanomas have a higher rate of metastasis and poorer prognosis.<xref ref-type="bibr" rid="article-151005.r12">[12]</xref>&#x000a0;Demirci et al reported that in 25 patients with diffuse melanoma, the rate of metastasis was 13%.<xref ref-type="bibr" rid="article-151005.r35">[35]</xref>&#x000a0;</p>
        <p>
<bold>Iris pigment epithelium adenocarcinoma</bold>
</p>
        <p>No reports of iris pigment epithelium adenocarcinoma metastasizing exist, although the literature is sparse. Prognosis favors early detection; many cases of adenocarcinoma arise from the malignant transformation of an iris pigment epithelium adenoma. Larger, invasive, and symptomatic tumors carry a poorer prognosis.<xref ref-type="bibr" rid="article-151005.r6">[6]</xref></p>
        <p>
<bold>Benign Lesions</bold>
</p>
        <p>
<bold>Iris cysts</bold>
</p>
        <p>The prognosis is dictated predominately by its invasiveness. However, stromal cysts carry a poorer prognosis than pigment epithelium cysts, and secondary cysts have a poorer prognosis than primary lesions, especially when the cyst occupies more than one-half of the anterior chamber.<xref ref-type="bibr" rid="article-151005.r22">[22]</xref></p>
        <p>
<bold>Iris nevus</bold>
</p>
        <p>The prognosis for iris nevi is generally favorable. Most&#x000a0;iris nevi remain stable and do not exhibit malignant transformation (see <bold>Image.&#x000a0;</bold>Iris Nevus Gonioscopy).<xref ref-type="bibr" rid="article-151005.r36">[36]</xref></p>
        <p>
<bold>Iris pigment epithelium adenoma</bold>
</p>
        <p>The prognosis of this tumor type is generally favorable, provided that malignant transformation does not occur. Iris adenomas require long-term monitoring for recurrence or transformation.<xref ref-type="bibr" rid="article-151005.r6">[6]</xref></p>
        <p>
<bold>Iris leiomyoma</bold>
</p>
        <p>The prognosis of iris leiomyomata is generally excellent. Long-term follow-up is important to monitor for any complications or disease recurrence, although recurrence is rare.<xref ref-type="bibr" rid="article-151005.r8">[8]</xref></p>
        <p>
<bold>Iridic nodules</bold>
</p>
        <p>Early diagnosis and treatment of underlying disease processes are proportionally related to prognosis in most iris nodules. In many cases, iris nodules indicate a later stage of disease; prompt diagnosis and referral for disease-specific treatment are imperative.<xref ref-type="bibr" rid="article-151005.r34">[34]</xref></p>
        <p>
<bold>Vascular tumors of the iris</bold>
</p>
        <p>The prognosis in the majority of patients presenting with vascular tumors is quite favorable. Prognoses tend to be poorer or more variable if the iris tumor is a manifestation of systemic disease.<xref ref-type="bibr" rid="article-151005.r37">[37]</xref></p>
      </sec>
      <sec id="article-151005.s10" sec-type="Complications">
        <title>Complications</title>
        <p>
<bold>Malignant Lesions</bold>
</p>
        <p>
<bold>Metastases to the iris</bold>
</p>
        <p>Due to the discohesive nature of metastases to the iris, secondary open-angle glaucoma may arise. Clinicians should proactively lower intraocular pressure, but filtering surgeries are not recommended.<xref ref-type="bibr" rid="article-151005.r2">[2]</xref></p>
        <p>
<bold>Iris melanoma</bold>
</p>
        <p>Secondary glaucoma is a common complication of iris melanoma. Filtering surgery for melanoma-associated glaucoma should be avoided due to tumor dissemination risk.<xref ref-type="bibr" rid="article-151005.r12">[12]</xref></p>
        <p>
<bold>Iris pigment epithelium adenoma and adenocarcinoma</bold>
</p>
        <p>These tumors can sometimes cause anterior displacement, stromal thinning, and erosion.<xref ref-type="bibr" rid="article-151005.r6">[6]</xref></p>
        <p>
<bold>Benign Lesions</bold>
</p>
        <p>
<bold>Iris cysts</bold>
</p>
        <p>Epithelial and stromal cysts may dislodge and become free-floating in the&#x000a0;anterior chamber or vitreous, but this is uncommon.<xref ref-type="bibr" rid="article-151005.r1">[1]</xref></p>
        <p>
<bold>Iris nevus</bold>
</p>
        <p>Many of the complications associated with iris nevi are due to either malignant transformation or deterioration of vision. These complications require a shift from clinical observation to intervention.<xref ref-type="bibr" rid="article-151005.r7">[7]</xref></p>
        <p>
<bold>Iris leiomyoma</bold>
</p>
        <p>Iris leiomyomata are typically not bothersome and amenable to long-term observation. However, in rare circumstances, the leiomyoma can exhibit uncharacteristic rapid growth and invade adjacent structures such as the angles. This behavior may warrant enucleation.<xref ref-type="bibr" rid="article-151005.r32">[32]</xref></p>
        <p>
<bold>Iridic nodules</bold>
</p>
        <p>Shields et al found that 34% of patients undergoing fine-needle aspirational biopsy experienced an immediate partial hyphema, although an adequate tissue sample was collected in 99% of patients. While the complications of iris nodules typically&#x000a0;reflect their systemic etiology, clinicians should be aware of the possible complications from invasive diagnostic tools; this is true for all iris tumors.<xref ref-type="bibr" rid="article-151005.r38">[38]</xref></p>
        <p>
<bold>Vascular tumors of the iris</bold>
</p>
        <p>The most common complication of vascular tumors is spontaneous hyphema; these typically resolve with topical treatments. Additionally, these tumors may complicate other procedures, such as phacoemulsification. A study from 2022 reported that 1 patient undergoing phacoemulsification with a concomitant vascular iridic tumor experienced mild intraoperative bleeding easily controlled by&#x000a0;increasing pressure in the anterior chamber with cohesive viscoelastic. It has been recommended to perform prophylactic photocoagulation with an argon laser to avoid intraoperative bleeding, although this practice is not universal.<xref ref-type="bibr" rid="article-151005.r11">[11]</xref></p>
      </sec>
      <sec id="article-151005.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with iris tumors should be educated regarding the risks of their particular neoplasm, particularly related to any potential underlying risks of malignant transformation. Close adherence to observation protocols is imperative. Additionally, as many iris tumors carry a significant risk of secondary glaucomatous change, patients must be educated to seek medical attention for any changes in vision, the acute onset of eye pain, or visible changes in the neoplasm.</p>
      </sec>
      <sec id="article-151005.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Most patients with an iris tumor notice the abnormality themselves or those around them note it. Patients will frequently present to a primary care practitioner or general optometrist; if the tumor is causing acute pain or vision changes, the patient may present to an urgent care clinic or emergency department. While many iridic lesions are benign, some are not, and a comprehensive ophthalmologic evaluation is necessary to determine the nature of the neoplasm. Prompt recognition of iris tumors with proper specialty referral is imperative for accurate diagnosis.</p>
        <p>The specific etiology of the iris tumor will determine the treatment plan, which may include referrals to subspecialty medical practitioners or ocular, medical, or surgical oncologists. Regardless of the etiology, many patients with iris tumors will require long-term monitoring of the lesion by eye care professionals.</p>
        <p>Thorough written and photographic documentation of the iris lesion(s) is critical to monitor changes in tumor size, growth patterns, and patient symptomatology. Continuity of care and patient adherence to long-term follow-up must be emphasized to improve vision outcomes, morbidity, and, in cases of malignant iris neoplasms, mortality.</p>
      </sec>
      <sec id="article-151005.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=151005&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=151005">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/benign-and-malignant-iris-tumors/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=151005">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/151005/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=151005">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-151005.s14">
        <fig id="article-151005.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Immunohistochemical Staining. The image depicts cells of an iris melanoma staining positive for immunohistochemical melanoma markers. Ophthalmology Department, Cairo University</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PHOTO-2022-01-08-13-39-31x1x" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-151005.s15">
        <fig id="article-151005.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Iris Melanoma. Anterior segment optical coherence tomography reveals iris melanoma, including a shadowing effect and poor visibility of the posterior surface of the iris due to the high reflectivity of the melanocytic lesion. Contributed by WJ Kheir, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Iris__Melanoma__AS__OCT" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-151005.s16">
        <fig id="article-151005.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Malignant Melanoma of Iris. Malignant melanoma of the iris with more amelanotic and vascular appearance. Contributed by&#x000a0;J Gilman, CRA, FOPS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Melanoma__1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-151005.s17">
        <fig id="article-151005.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Malignant Melanoma of Iris Typical Presentation. Malignant melanoma of the iris with typical melanotic presentation. Contributed by J Gilman, CRA, FOPS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Melanoma__2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-151005.s18">
        <fig id="article-151005.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Melanotic Malignant Melanoma. Large melanotic malignant melanoma observed via gonioscopy. Courtesy of&#x000a0;James Gilman, CRA, FOPS, John A. Moran Eye Center, University of Utah</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Melanoma__3" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-151005.s19">
        <fig id="article-151005.image.f6" position="float" orientation="portrait">
          <caption>
            <p>Iris Nevus. Iris nevus with surrounding discoloration. Contributed by J Gilman, CRA, FOPS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Nevus__1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-151005.s20">
        <fig id="article-151005.image.f7" position="float" orientation="portrait">
          <caption>
            <p>Iris Nevus Gonioscopy Contributed by J Gilman, CRA, FOPS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Nevus__2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-151005.s21">
        <title>References</title>
        <ref id="article-151005.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shields</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Manalac</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jumroendararasame</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Review of cystic and solid tumors of the iris.</article-title>
            <source>Oman J Ophthalmol</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>159</fpage>
            <page-range>159-64</page-range>
            <pub-id pub-id-type="pmid">24379549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shields</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Kalafatis</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Gad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laiton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>AMV</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lally</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Metastatic tumours to the eye. Review of metastasis to the iris, ciliary body, choroid, retina, optic disc, vitreous, and/or lens capsule.</article-title>
            <source>Eye (Lond)</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>809</fpage>
            <page-range>809-814</page-range>
            <pub-id pub-id-type="pmid">35306540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalirai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dodson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Faqir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Damato</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Coupland</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing.</article-title>
            <source>Br J Cancer</source>
            <year>2014</year>
            <month>Sep</month>
            <day>23</day>
            <volume>111</volume>
            <issue>7</issue>
            <fpage>1373</fpage>
            <page-range>1373-80</page-range>
            <pub-id pub-id-type="pmid">25058347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>RONES</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>ZIMMERMAN</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>The prognosis of primary tumors of the iris treated by iridectomy.</article-title>
            <source>AMA Arch Ophthalmol</source>
            <year>1958</year>
            <month>Aug</month>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>193</fpage>
            <page-range>193-205</page-range>
            <pub-id pub-id-type="pmid">13558786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krantz</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Dave</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Komatsubara</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Marr</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Carvajal</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Uveal melanoma: epidemiology, etiology, and treatment of primary disease.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2017</year>
            <volume>11</volume>
            <fpage>279</fpage>
            <page-range>279-289</page-range>
            <pub-id pub-id-type="pmid">28203054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dryja</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Zakov</surname>
                <given-names>ZN</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Adenocarcinoma arising from the epithelium of the iris and ciliary body.</article-title>
            <source>Int Ophthalmol Clin</source>
            <year>1980</year>
            <season>Summer</season>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>177</fpage>
            <page-range>177-90</page-range>
            <pub-id pub-id-type="pmid">6995386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shields</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Kaliki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hutchinson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nickerson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kancherla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peshtani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nakhoda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kocher</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kolbus</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Garoon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Iris nevus growth into melanoma: analysis of 1611 consecutive eyes: the ABCDEF guide.</article-title>
            <source>Ophthalmology</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>120</volume>
            <issue>4</issue>
            <fpage>766</fpage>
            <page-range>766-72</page-range>
            <pub-id pub-id-type="pmid">23290981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yeaney</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Platt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Primary iris leiomyoma.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2017</year>
            <season>May-Jun</season>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>366</fpage>
            <page-range>366-370</page-range>
            <pub-id pub-id-type="pmid">27890619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lubs</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Formas</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Djokic</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Lisch nodules in neurofibromatosis type 1.</article-title>
            <source>N Engl J Med</source>
            <year>1991</year>
            <month>May</month>
            <day>02</day>
            <volume>324</volume>
            <issue>18</issue>
            <fpage>1264</fpage>
            <page-range>1264-6</page-range>
            <pub-id pub-id-type="pmid">1901624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Myers</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Lauer</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Iris nodules associated with infectious uveitis.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2002</year>
            <month>Sep</month>
            <volume>86</volume>
            <issue>9</issue>
            <fpage>969</fpage>
            <page-range>969-74</page-range>
            <pub-id pub-id-type="pmid">12185117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calleja-Garc&#x000ed;a</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Su&#x000e1;rez-Baraza</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Menc&#x000ed;a-Guti&#x000e9;rrez</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Iris Vascular Malformation with 360-Degree Iridocorneal Angle Affectation.</article-title>
            <source>Case Rep Ophthalmol Med</source>
            <year>2020</year>
            <volume>2020</volume>
            <fpage>5913636</fpage>
            <pub-id pub-id-type="pmid">32566340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaliki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Uveal melanoma: relatively rare but deadly cancer.</article-title>
            <source>Eye (Lond)</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>241</fpage>
            <page-range>241-257</page-range>
            <pub-id pub-id-type="pmid">27911450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>VRABEC</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>SOUKUP</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>MALIGNANT EPITHELIOMA OF THE PIGMENTED EPITHELIUM OF THE HUMAN IRIS.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1963</year>
            <month>Sep</month>
            <volume>56</volume>
            <fpage>403</fpage>
            <page-range>403-9</page-range>
            <pub-id pub-id-type="pmid">14064886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laino</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Jagirdar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Duffy</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Soyer</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Sturm</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Iris pigmented lesions as a marker of cutaneous melanoma risk: an Australian case-control study.</article-title>
            <source>Br J Dermatol</source>
            <year>2018</year>
            <month>May</month>
            <volume>178</volume>
            <issue>5</issue>
            <fpage>1119</fpage>
            <page-range>1119-1127</page-range>
            <pub-id pub-id-type="pmid">29315480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shields</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Kancherla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vijayvargiya</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Suriano</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Kolbus</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Badami</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Voluck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Kansal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Bianciotto</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Clinical survey of 3680 iris tumors based on patient age at presentation.</article-title>
            <source>Ophthalmology</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>119</volume>
            <issue>2</issue>
            <fpage>407</fpage>
            <page-range>407-14</page-range>
            <pub-id pub-id-type="pmid">22035581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shields</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Mercado</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>G&#x000fc;nd&#x000fc;z</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eagle</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Adenoma of the iris pigment epithelium: a report of 20 cases: the 1998 Pan-American Lecture.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>117</volume>
            <issue>6</issue>
            <fpage>736</fpage>
            <page-range>736-41</page-range>
            <pub-id pub-id-type="pmid">10369583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shields</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Observations on intraocular leiomyomas.</article-title>
            <source>Trans Pa Acad Ophthalmol Otolaryngol</source>
            <year>1990</year>
            <volume>42</volume>
            <fpage>945</fpage>
            <page-range>945-50</page-range>
            <pub-id pub-id-type="pmid">2084991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Postolache</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Parsa</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>Brushfield spots and W&#x000f6;lfflin nodules unveiled in dark irides using near-infrared light.</article-title>
            <source>Sci Rep</source>
            <year>2018</year>
            <month>Dec</month>
            <day>21</day>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>18040</fpage>
            <pub-id pub-id-type="pmid">30575783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eguilior &#x000c1;lvarez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marticorena-&#x000c1;lvarez</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Multimodal Imaging in Iris Vascular Tumors: A Case Series.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>11</issue>
            <fpage>e31741</fpage>
            <pub-id pub-id-type="pmid">36569711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McLean</surname>
                <given-names>IW</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Gamel</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1983</year>
            <month>Oct</month>
            <volume>96</volume>
            <issue>4</issue>
            <fpage>502</fpage>
            <page-range>502-9</page-range>
            <pub-id pub-id-type="pmid">6624832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shields</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Augsburger</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Sanborn</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Adenoma of the iris-pigment epithelium.</article-title>
            <source>Ophthalmology</source>
            <year>1983</year>
            <month>Jun</month>
            <volume>90</volume>
            <issue>6</issue>
            <fpage>735</fpage>
            <page-range>735-9</page-range>
            <pub-id pub-id-type="pmid">6888863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Georgalas</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Petrou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Papaconstantinou</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brouzas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Koutsandrea</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kanakis</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Iris cysts: A comprehensive review on diagnosis and treatment.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2018</year>
            <season>May-Jun</season>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>347</fpage>
            <page-range>347-364</page-range>
            <pub-id pub-id-type="pmid">28882598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paul</surname>
                <given-names>TO</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Webster</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Congenital intrastromal epithelial cyst of the iris.</article-title>
            <source>Ann Ophthalmol</source>
            <year>1994</year>
            <season>May-Jun</season>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>94</fpage>
            <page-range>94-6</page-range>
            <pub-id pub-id-type="pmid">7944162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shields</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bianciotto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kligman</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Vascular tumors of the iris in 45 patients: the 2009 Helen Keller Lecture.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>128</volume>
            <issue>9</issue>
            <fpage>1107</fpage>
            <page-range>1107-13</page-range>
            <pub-id pub-id-type="pmid">20837792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sabazade</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Herrspiegel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>St&#x000e5;lhammar</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter.</article-title>
            <source>BMC Cancer</source>
            <year>2021</year>
            <month>Nov</month>
            <day>24</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>1270</fpage>
            <pub-id pub-id-type="pmid">34819035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rasmussen</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>NF1 gene and neurofibromatosis 1.</article-title>
            <source>Am J Epidemiol</source>
            <year>2000</year>
            <month>Jan</month>
            <day>01</day>
            <volume>151</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-40</page-range>
            <pub-id pub-id-type="pmid">10625171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zamir</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Krishnakumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aiello Leverant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dugel</surname>
                <given-names>PU</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Juvenile xanthogranuloma masquerading as pediatric chronic uveitis: a clinicopathologic study.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2001</year>
            <season>Sep-Oct</season>
            <volume>46</volume>
            <issue>2</issue>
            <fpage>164</fpage>
            <page-range>164-71</page-range>
            <pub-id pub-id-type="pmid">11578649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conway</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Golchet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Ultrasound biomicroscopy: role in diagnosis and management in 130 consecutive patients evaluated for anterior segment tumours.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>89</volume>
            <issue>8</issue>
            <fpage>950</fpage>
            <page-range>950-5</page-range>
            <pub-id pub-id-type="pmid">16024841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pilling</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ball</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>The utility of anterior segment optical coherence tomography in monitoring intraocular epithelial cysts in children: a mini case series.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>94</volume>
            <issue>9</issue>
            <fpage>1265</fpage>
            <pub-id pub-id-type="pmid">20511634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krohn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sundal</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Fr&#x000f8;ystein</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Topography and clinical features of iris melanoma.</article-title>
            <source>BMC Ophthalmol</source>
            <year>2022</year>
            <month>Jan</month>
            <day>03</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <pub-id pub-id-type="pmid">34980044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skalet</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Husvogt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Optical Coherence Tomography Angiography Characteristics of Iris Melanocytic Tumors.</article-title>
            <source>Ophthalmology</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>124</volume>
            <issue>2</issue>
            <fpage>197</fpage>
            <page-range>197-204</page-range>
            <pub-id pub-id-type="pmid">27856029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomar</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Finger</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Iacob</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Intraocular leiomyoma: Current concepts.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2020</year>
            <season>Jul-Aug</season>
            <volume>65</volume>
            <issue>4</issue>
            <fpage>421</fpage>
            <page-range>421-437</page-range>
            <pub-id pub-id-type="pmid">31923479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ocampo</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Baltatzis</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Surgical excision of iris nodules in the management of sarcoid uveitis.</article-title>
            <source>Ophthalmology</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>108</volume>
            <issue>7</issue>
            <fpage>1296</fpage>
            <page-range>1296-9</page-range>
            <pub-id pub-id-type="pmid">11425690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yeomans</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Knox</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Murgatroyd</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>Ocular inflammatory pseudotumor associated with propranolol therapy.</article-title>
            <source>Ophthalmology</source>
            <year>1983</year>
            <month>Dec</month>
            <volume>90</volume>
            <issue>12</issue>
            <fpage>1422</fpage>
            <page-range>1422-5</page-range>
            <pub-id pub-id-type="pmid">6687156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Demirci</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Eagle</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Honavar</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Diffuse iris melanoma: a report of 25 cases.</article-title>
            <source>Ophthalmology</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>109</volume>
            <issue>8</issue>
            <fpage>1553</fpage>
            <page-range>1553-60</page-range>
            <pub-id pub-id-type="pmid">12153810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foti</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Travali</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farina</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Palmucci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spatola</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Raffaele</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Salamone</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Caltabiano</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Broggi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Puzzo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reibaldi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Longo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vigneri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Avitabile</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ettorre</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Basile</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part I: MR imaging with pathologic correlation and technical considerations.</article-title>
            <source>Insights Imaging</source>
            <year>2021</year>
            <month>Jun</month>
            <day>03</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <pub-id pub-id-type="pmid">34080069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas-Sohl</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Vaslow</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Maria</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Sturge-Weber syndrome: a review.</article-title>
            <source>Pediatr Neurol</source>
            <year>2004</year>
            <month>May</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>303</fpage>
            <page-range>303-10</page-range>
            <pub-id pub-id-type="pmid">15165630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151005.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shields</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Manquez</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Ehya</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mashayekhi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Danzig</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Fine-needle aspiration biopsy of iris tumors in 100 consecutive cases: technique and complications.</article-title>
            <source>Ophthalmology</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>113</volume>
            <issue>11</issue>
            <fpage>2080</fpage>
            <page-range>2080-6</page-range>
            <pub-id pub-id-type="pmid">17074566</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
